Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGFA), and FDA has approved its application for the treatment of metastatic colorectal cancer (mCRC), non-small cell lung cancer (NSCLC) and advanced ovarian cancer combined with the chemotherapy drugs. Here, VEGFA is linked to metastatic colorectal cancer.